Skip to main content
SpringerLink
Log in

Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients

  • Original Article
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

Abstract

Objective

To evaluate the role of palliative stereotactic body radiation therapy (SBRT) in Barcelona Clinic Liver Cancer stage‑C (BCLC-C) hepatocellular carcinoma (HCC) patients who are not suitable for other loco-regional therapies.

Materials and methods

It is an observational retrospective study done between May 2020 and September 2021. The data were collected from 35 patients of advanced HCC who underwent SBRT. Patients of Child Pugh status (CPs) A5-B7 and with a liver reserve of ≥ 700cc were included. Local control (LC), overall survival (OS) and adverse events including decompensation were carefully recorded.

Results

In the cohort, Portal vein and IVC tumor thrombosis were present in 33 (94.3%) and 8 (22.85%) patients, respectively. Lung and nodal metastasis were found in 11 (31.4%) and 21 (60%) of patients, respectively. The median gross tumor volume (GTV) was 563cc (range 80–1925cc). The median SBRT dose prescription was 35 Gy (range 25–40 Gy) in 5–10 fractions. Post radiation therapy, there was improvement in pain and discomfort in 24 out of 29 (82.75%) and 18 out of 23 (78%) patients respectively. Also bone metastasis related pain was improved in all 3 (100%) patients.

One year LC, and OS were 80% and 30% respectively. On multivariate analysis, the GTV volume > 750cc and PIVKA-II > 8000 mAU/ml remained the predictor factor for poor OS. Post SBRT, change in child-pugh score by 1 point was observed in 7 patients (20%) which was managed conservatively.

Conclusion

SBRT is a safe and feasible option for BCLC‑C HCC. It not only improves the quality of life by symptom control but also results in good LC and OS with acceptable toxicity. SBRT should be considered in a multidisciplinary fashion for patients presenting with advanced HCCs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

    Article  PubMed  Google Scholar 

  2. Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S et al (2020) Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 50:15–46

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cheng S, Yang J, Shen F, Zhou W, Wang Y, Cong W et al (2016) Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus—Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget 7(26):40816–40829. https://doi.org/10.18632/oncotarget.8386

    Article  PubMed  PubMed Central  Google Scholar 

  4. Que J, Wu HC, Lin CH, Huang CI, Li LC, Ho CH (2020) Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. Medicine (Baltimore) 99(13):e19660. https://doi.org/10.1097/MD.0000000000019660

    Article  CAS  PubMed  Google Scholar 

  5. Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á (2021) Stereotactic radiotherapy for hepatocellular carcinoma, radiosensitization strategies and radiation-immunotherapy combination. Cancers (Basel) 13(2):192. https://doi.org/10.3390/cancers13020192

    Article  CAS  PubMed  Google Scholar 

  6. Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC et al (2016) Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer 16(1):834. https://doi.org/10.1186/s12885-016-2894-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, Zhang B, Wu J, Li Q, Hu Q, Shen L, Bai X, Liang T, Wei Q (2018) Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 13(1):188. https://doi.org/10.1186/s13014-018-1136-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Choi CKK, Ho CHM, Wong MYP, Leung RWK, Wong FCS, Tung SY et al (2021) Long-term results of palliative stereotactic radiotherapy of barcelona clinic liver cancer stage C hepatitis B–related hepatocellular carcinoma. Hong Kong J Radiol 24:81–86

    Article  Google Scholar 

  9. Dawson LA, Zhu A, Knox J et al (2012) Radiation therapy oncology group Rtog 1112 randomized phase iii study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma

    Google Scholar 

  10. Cancer Institute N (2017) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://www.meddra.org/. Accessed 4 Nov 2018

  11. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60. https://doi.org/10.1055/s-0030-1247132

    Article  CAS  PubMed  Google Scholar 

  12. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á et al (2021) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. https://doi.org/10.1016/j.jhep.2021.11.018

    Article  PubMed  PubMed Central  Google Scholar 

  13. Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M et al (2022) External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol 12(1):28–51. https://doi.org/10.1016/j.prro.2021.09.004

    Article  PubMed  Google Scholar 

  14. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576

    Article  CAS  PubMed  Google Scholar 

  15. Patidar Y, Garg L, Mukund A, Sarin SK (2019) Early experience of combination therapy of transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma measuring 3–7 cm. Indian J Radiol Imaging 29(1):47–52. https://doi.org/10.4103/ijri.IJRI_352_18

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chopra S, George K, Engineer R, Rajamanickam K, Nojin S, Joshi K et al (2019) Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. Br J Radiol 92(1101):20181053. https://doi.org/10.1259/bjr.20181053

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yeoh KW, Prawir A, Bin Saad MZ, Lee KM, Lee EMH, Low GK et al (2020) Vinorelbine augments radiotherapy in hepatocellular carcinoma. Cancers 12:872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31:1631–1639

    Article  PubMed  Google Scholar 

  19. Ohri N, Tome WA, Mendez Romero A, Miften M, Ten Haken RK, Dawson LA et al (2021) Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 110(1):188–195. https://doi.org/10.1016/j.ijrobp.2017.12.288

    Article  PubMed  Google Scholar 

  20. Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M et al (2017) Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol. https://doi.org/10.1186/s13014-017-0851-7

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hammad AY, Robbins JR, Turaga KK, Christians KK, Gamblin TC, Johnston FM (2017) Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. Ann Palliat Med 6(1):26–35. https://doi.org/10.21037/apm.2016.11.02

    Article  PubMed  Google Scholar 

  22. Hawkins MA, Dawson LA (2006) Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106:1653–1663

    Article  PubMed  Google Scholar 

  23. Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, Nakagawa K (2015) Japanese Radiological Society multi-institutional SBRT study group (JRS-SBRTSG). Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res 56(3):561–567. https://doi.org/10.1093/jrr/rru130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kuo H‑T, Que J, Lin L‑C, Yang C‑C, Koay L‑B, Lin C‑H (2017) Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma. Medicine 96:e9249. https://doi.org/10.1097/MD.0000000000009249

    Article  PubMed  PubMed Central  Google Scholar 

  25. Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H, Allgaeuer M, Becker G et al (2019) The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 19(1):173. https://doi.org/10.1186/s12885-019-5362-5

    Article  PubMed  PubMed Central  Google Scholar 

  26. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7

    Article  CAS  PubMed  Google Scholar 

  27. Nandennavar MI, Karpurmath SV, Mandakalatur G, Prasad AE (2017) Clinical profile of hepatocellular carcinoma and experience with sorafenib from a tertiary cancer centre in Southern India. Int J Res Med Sci 5:379–383

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India

    Deepti Sharma MD,  Deepak Thaper PhD, Rose Kamal PhD & Hanuman Prasad Yadav MD

Authors
  1. Deepti Sharma MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepak Thaper PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rose Kamal PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hanuman Prasad Yadav MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepti Sharma MD.

Ethics declarations

Conflict of interest

D. Sharma, D. Thaper, R. Kamal and H.P. Yadav declare that they have no competing interests.

Additional information

Data Availability Statement

Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, D., Thaper, D., Kamal, R. et al. Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients. Strahlenther Onkol 199, 838–846 (2023). https://doi.org/10.1007/s00066-023-02065-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-023-02065-x

Keywords

Search

Navigation